文献速递免疫规划

不同糖基突变联合V1/V2区或V3冠部缺失的HIV-1 gp140的抗原性与免疫原性

Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
PubMed 文献 · Vaccine · 2019-09-26

研究设计了一系列HIV-1 gp140构建体,单独或联合去除N276/N463糖基、删除V1/V2区和V3冠部,在哺乳动物细胞中纯化后体外检测与广谱中和抗体及非中和抗体的结合,并在小鼠中通过DNA-DNA或DNA-蛋白 prime-boost 策略评估免疫原性。结果显示去除N276/N463糖基联合删除V1/V2区可增强与CD4结合位点靶向广谱中和抗体VRC01和3BNC117及CD4诱导表位靶向非中和抗体A32、17b和F425 A1g8的结合,但进一步删除V3冠部则结合能力略有下降;上述突变未能通过两种策略诱导更高的Env特异性IgG应答,中和试验也未显示野生型与突变体gp140s之间的明显差异。

要点

  • 去除N276/N463糖基联合删除V1/V2区可暴露CD4结合位点和CD4诱导表位。
  • 上述糖基去除与V1/V2区删除的联合突变未能在小鼠中增强广谱中和抗体的诱导。
  • 所建立的gp140生产及抗原性/免疫原性分析策略可用于进一步疫苗设计与评估。

核心结论

  • 去除N276/N463糖基和删除V1/V2区可暴露CD4结合位点和CD4诱导表位,但这种暴露本身似乎不足以增强小鼠中广谱中和抗体的诱导,提示需要额外修饰和/或免疫策略。

研究设计与样本

  • 研究设计了一系列HIV-1 gp140构建体,单独或联合去除N276/N463糖基、删除V1/V2区和V3冠部。
  • 所有构建体在哺乳动物细胞中表达并纯化,表达水平相当且主要以三聚体形式表达。
  • 体外检测gp140s与广谱中和抗体及非中和抗体的结合,并在小鼠中通过DNA-DNA或DNA-蛋白 prime-boost 策略评估免疫原性。

主要发现

  • 去除N276/N463糖基联合删除V1/V2区增强了gp140s与CD4结合位点靶向广谱中和抗体VRC01和3BNC117以及CD4诱导表位靶向非中和抗体A32、17b和F425 A1g8的结合。
  • 在gp140突变体中进一步删除V3冠部则对这些抗体的结合能力略有下降。
  • 上述突变通过DNA-DNA或DNA-蛋白 prime-boost 策略均未导致小鼠中Env特异性IgG应答的更高诱导。
  • 中和试验未显示野生型与突变体gp140s之间的明显差异。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The carbohydrate moieties on HIV-1 envelope glycoprotein (Env) act as shields to mask conserved neutralizing epitopes, while the hyperimmunogenic variable regions are immunodominant in inducing non-neutralizing antibodies, representing the major challenge for using Env as a vaccine candidate to induce broadly neutralizing antibodies (bNAbs). In this study, we designed a series of HIV-1 gp140 constructs with the removal of N276/N463 glycans, deletion of the V1/V2 region and the V3 crown, alone or in combination. We first demonstrated that all the constructs had a comparable level of expression and were mainly expressed as trimers. Following purification of gp140s from mammalian cells, we measured their binding to bNAbs and non-NAbs in vitro and capability in inducing bNAbs in vivo. Antibody binding assay showed that removal of N276/N463 glycans together with the deletion of V1/V2 region enhanced the binding of gp140s to CD4-binding site-targeting bNAbs VRC01 and 3BNC117, and CD4-induced epitopes-targeting non-NAbs A32, 17b and F425 A1g8, whereas further deletion of V3 crown in the gp140 mutants demonstrated slightly compromised binding capability to these Abs. Immunogenicity study showed that the above mutations did not lead to the induction of a higher Env-specific IgG response via either DNA-DNA or DNA-protein prime-boost strategies in mice, while neutralization assay did not show an apparent difference between wild type and mutated gp140s. Taken together, our results indicate that removal of glycans at N276/N463 and deletion of the V1/V2 region can expose the CD4-binding site and CD4-induced epitopes, but such exposure alone appears incapable of enhancing the induction of bNAbs in mice, informing that additional modification or/and immunization strategies are needed. In addition, the strategies which we established for producing gp140 proteins and for analyzing the antigenicity and immunogenicity of gp140 provide useful means for further vaccine design and assessment.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fu M, Hu K, Hu H, et al. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion. Vaccine. 2019. PMID: 31564450. doi:10.1016/j.vaccine.2019.09.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。